Evidence map›Paper›PMID 42811164›Full record

ArticleJournal of bone and mineral metabolism2026

Comparative effects of roxadustat and epoetin beta on lumbar trabecular BMD in dialysis patients.

Mostafa Alaskary, Mohamed A Sobh, Mohamed Ashraf Fouda, Dina Abd Elnasser Rizk, Aya Atef Warda, Wael Ibrahim Mortada, Mohamed Maher Elashmawy, Mohamed Abdalbary

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06917950 (Effect of Roxadustat on Bone and Neuropsychiatric Aspects in End Stage Kidney Disease Patients on Hemodialysis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06917950 phase1 / phase2recruitingnot on this map

Effect of Roxadustat on Bone and Neuropsychiatric Aspects in End Stage Kidney Disease Patients on Hemodialysis

TypeinterventionalSponsorMansoura UniversityRan2025 to 2025Enrolled46ConditionsKidney Failure,Chronic, Anemia in End Stage Renal Disease, Depression Anxiety DisorderArmsRoxadustat, Conventional Anemia Management
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mostafa AlaskaryDialysis and Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. mostafa2110@mans.edu.eg.
Mohamed A SobhDialysis and Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mohamed Ashraf FoudaDialysis and Transplantation Unit, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Dina Abd Elnasser RizkDepartment of Radiology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Aya Atef WardaDepartment of Radiology, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Wael Ibrahim MortadaClinical Chemistry Lab, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mohamed Maher ElashmawyRheumatology, Physical Medicine and Rehabilitation Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed AbdalbaryNephrology and Dialysis Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnemia treatment agents may have effects beyond hemoglobin, yet whether hypoxia-inducible factor prolyl hydroxylase inhibition influences bone in dialysis remains uncertain. We compared roxadustat with epoetin beta for lumbar trabecular volumetric bone mineral density (vBMD) measured by quantitative computed tomography (QCT). MATERIALS AND

methodsIn this single-center, open-label, exploratory randomized trial, 46 adults receiving maintenance hemodialysis were assigned 1:1 to roxadustat or epoetin beta for 6 months. The primary outcome was the baseline-adjusted between-group difference in average lumbar trabecular vBMD at 6 months. Vertebral-level analyses were exploratory.

resultsAll participants completed follow-up. Adjusted mean average lumbar vBMD at 6 months was 159 mg/cm

conclusionRoxadustat did not demonstrate superiority over epoetin beta for average lumbar trabecular vBMD over 6 months. These randomized QCT-based estimates address an important evidence gap and may inform larger, longer-term skeletal studies in dialysis.

trial registrationClinicalTrials.gov NCT06917950; registered 27 March 2025.

Indexed as

Bone mineral densityEpoetin betaHemodialysisQuantitative computed tomographyRoxadustat

Identifiers

PMID42811164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.